Epidermal growth factor receptor, somatostatin and Bcl-2 in human pancreatic tumor xenografts: An immunohistochemical study

Pathology and Oncology Research

Volumn 5, Issue 2, 1999, Pages 146-151

  Zalatnai, Attila ^a  

^a SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

Author keywords

Bcl 2; Pancreas tumor; Somatostatin; Xenograft

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN BCL 2; SOMATOSTATIN;

ARTICLE; CANCER SURVIVAL; CELL DEATH; CELL PROLIFERATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOREACTIVITY; LEIOMYOSARCOMA; PANCREAS TUMOR; PHENOTYPE; PROTEIN EXPRESSION; SAMPLING; TUMOR XENOGRAFT;

EID: 0032815246     PISSN: 12194956     EISSN: None     Source Type: Journal    
DOI: 10.1053/paor.1999.0176     Document Type: Article

References (40)

1. Bell K, Bronner M P, Pasha T. Expression of proliferating cell nuclear antigen in gastrointestinal tract lesions and its relationship to bcl-2 expression. Pathobiology. 64:1996;91-98.
2. Berchem G J, Bosseler M, Sugars L Y. Androgens induce resistance to bcl-2-mediated apoptosis in LNCaP prostate cancer cells. Cancer Res. 55:1995;735-738.
3. Bocsi J, Zalatnai A. Establishment and long term xenografting of human pancreatic carcinomas in immunosuppressed mice: Changes and stability in morphology, DNA ploidy and proliferative activity. J Cancer Res Clin Oncol. 125:1999;9-19.
4. Chester J F, Gaissert H A, Ross J S. Pancreatic cancer in the Syrian golden hamster induced by N-Nitrosobis(2-oxopropyl) amine: cocarcinogenic effect of epidermal growth factor. Cancer Res. 46:1986;2954-2957.
5. Fisher W E, Doran T A, Muscarella I IP. Expression of somatostatin receptor subtype 1 - 5 genes in human pancreatic cancer. J Natl Cancer Inst. 90:1998;322-324.
6. Gansauge F, Gansauge S, Schmidt E. Prognostic significance of molecular alterations in human pancreatic carcinoma - an immunohistochemical study. Langenbecks Arch Surg. 383:1998;152-155.
7. Gower W R, Risch R M, Godellas C V. HPAC, a new human glucocorticoid-sensitive pancreatic ductal adenocarcinoma cell line. In Vitro Cell Developm Biol Anim. 30:1994;151-161.
8. Hockenbery D M, Zutter M, Hickey W. BCL-2 protein is topographically restricted in tissues characterized by apoptotic cell death. Proc Natl Acad Sci USA. 88:1991;6961-6966.
9. Kuwashima Y, Kobayashi Y, Kurosumi M. Inverse correlation between bcl-2 expression and cell growth fraction in human endometrial adenocarcinoma tissue. Anticancer Res. 17:1997;3773-3776.
10. Lemoine N R, Hughes C M, Barton C M. The epidermal growth factor receptor in human pancreatic cancer. J Pathol. 166:1992;7-12.
11. Makinen K, Hakala T, Lipponen P. Clinical contribution of bcl-2, p53 and Ki-67 proteins in pancreatic ductal adenocarcinoma. Anticancer Res. 18:1998;615-618.
12. Matsuo H, Maruo T, Samoto T. Increased expression of Bcl-2 protein in human uterine leiomyoma and its up-regulation by progesterone. J Clin Endocrinol Metab. 82:1997;293-299.
13. Mejia M C, Navarro S, Pellin A. Study of bcl-2 protein expression and the apoptosis phenomenon in neuroblastoma. Anticancer Res. 18:1998;801-806.
14. Nakanishi H, Ohsawa M, Naka N. Immunohistochemical detection of bcl-2 and p53 proteins and apoptosis in soft tissue sarcoma: their correlations with prognosis. Oncology. 54:1997;238-244.
15. Ohshio G, Suwa H, Imamura T. An immunohistochemical study of bcl-2 and p53 protein expression in pancreatic carcinomas. Scand J Gastroenterol. 33:1998;535-539.
16. Poston G J, Townsend C M, Rajareman S. Effect of somatostatin and tamoxifen on the growth of human pancreatic cancers in nude mice. Pancreas. 5:1990;151-157.
17. Qin Y, Ertl T, Groot K. Somatostatin analog RC-160 inhibits growth of CFPAC-1 human pancreatic cancer cells in vitro and intracellular proliferation of cyclic adenosine monophosphate. Int J Cancer. 60:1995;694-700.
18. Redding T W, Schally A V. Inhibition of growth of pancreatic carcinomas in animal models by analogs of hypothalamic hormones. Proc Natl Acad Sci USA. 81:1984;248-252.
19. Reed J C. Bcl-2 family proteins and their hormonal control of cell life and death in normalcy and neoplasia. Vitamins and Hormones. 53:1997;99-138.
20. Robertson J F, Watson S A, Hardcastle J D. Effect of gastrointestinal hormones and synthetic analogues on the growth of pancreatic cancer. Int J Cancer. 63:1995;69-75.
21. Rosenberg L, Barkun A N, Denis M H. Low dose octreotide and tamoxifen in the treatment of adenocarcinoma of the pancreas. Cancer. 75:1995;23-28.
22. Saegusa M, Okayasu I. Bcl-2 is closely correlated with favorable prognostic factors and inversely associated with p53 protein accumulation in endometrial carcinomas: immunohistochemical and polymerase chain reaction/loss of heterozygosity findings. J Cancer Res Clin Oncol. 123:1997;429-434.
23. Sinicrope F A, Evans D B, Leach S D. Bcl-2 and p53 expression in resectable pancreatic adenocarcinomas: association with clinical outcome. Clin Cancer Res. 2:1996;2015-2022.
24. Stefanaki K, Rontogiannis D, Vamvouka C. Immunohistochemical detection of bcl-2, p53, mdm2 and p21/waf1 proteins in small-cell lung carcinomas. Anticancer Res. 18:1998;1167-1173.
25. Szende B, Zalatnai A, Schally A V. Programmed cell death (apoptosis) in pancreatic cancers of hamsters after treatment with analogs of both luteinizing hormone-releasing hormone and somatostatin. Proc Natl Acad Sci USA. 86:1989;1643-1647.
26. Takeda Y, Escribano M J. Effects of insulin and somatostatin on the growth and the colony formation of two human pancreatic cancer cell lines. J Cancer Res Clin Oncol. 117:1991;416-420.
27. Teixeira C, Reed J C, Pratt M A. Estrogen promotes chemotherapeutic drug resistance by a mechanism involving Bcl-2 protooncogene expression in human breast cancer cells. Cancer Res. 55:1995;3902-3907.
28. Uegaki K, Nio Y, Inoue Y. Clinicopathological significance of epidermal growth factor and its receptor in human pancreatic cancer. Anticancer Res. 17:1997;3841-3847.
29. Upp J R, Olson D, Poston G J. Inhibition of growth of two human pancreatic adenocarcinomas in vivo by somatostatin analog SMS 201-995. Am J Surg. 155:1983;29-35.
30. Vidal C, Rauly I, Zeggari M. Up-regulation of somatostatin receptors by epidermal growth factor and gastrin in pancreatic cancer cells. Mol Pharmacol. 46:1994;97-104.
31. Vinter-Jensen L, Juhl C O, Teglbjaerg P S. Systemic treatment with epidermal growth factor in pigs induces ductal proliferations in the pancreas. Gastroenterology. 113:1997;1367-1374.
32. Wada M, Doi R, Hosotani R. Expression of bcl-2 and PCNA in duct cells after pancreatic duct ligation in rats. Pancreas. 15:1997;176-182.
33. Wada M, Hosotani R, Lee J U. An exogenous cdk inhibitor, butyrolactone-1, induces apoptosis with increased Bax/Bcl-2 ratio in p53-mutated pancreatic cancer cells. Anticancer Res. 18:1998;2559-2566.
34. Wang D G, Johnston C F, Buchanan K D. Oncogene expression in gastroenteropancreatic neuroendocrine tumors: implications for pathogenesis. Cancer. 80:1997;668-675.
35. Weckbecker G, Tolcsvai L, Liu R. Preclinical studies on the anticancer activity of somatostatin analogue octreotide (SMS 201-995). Metabolism. 41:1992;99-103.
36. Witty J P, Jensen R A, Johnson A L. Expression and localization of Bcl-2 related proteins in human ovarian cancers. Anticancer Res. 18:1998;1223-1230.
37. Yan J J, Chen F F, Tsai Y C, Jin Y T. Immunohistochemical detection of bcl-2 protein in small cell carcinomas. Oncology. 53:1996;6-11.
38. Zalatnai A, Bocsi J, Timár F. Establishment and characterization of a new transplantable pancreatic cancer xenograft (PZX-5) in immunosuppressed mice. Internatl J Pancreatol. 23:1998;51-62.
39. Zalatnai A, Kovács M, Flautner L. Pancreatic leiomyosarcoma. Case report with immunohistochemical and flow cytometric studies. Virchows Arch. 432:1998;469-472.
40. Zalatnai A, Schally A V. Treatment of the N-Nitrosobis/2-oxo-propyl/amine-induced pancreatic cancer in Syrian golden hamsters with D-Trp-6-LH-RH and somatostatin analog RC-160 microcapsules. Cancer Res. 49:1989;1810-1815.